Figure 7.
Exosomal MIF induces TMZ resistance in vivo
(A) Schematic of the in vivo model: BALB/c mice were orthotopically injected intracranially with 2.5 × 105 U87/luciferase cells that were pre-incubated with PBS or 40 μg/mL exosomes from U87 TR, U87TR-NC, or U87TR-MIF-sh cells for 6 days (n = 5 per group). (B) Representative pseudocolor bioluminescence images of orthotopic tumors. (C) Kaplan-Meier survival curve of mice with intracranial xenografts derived from indicated exosomes-treated U87/luciferase cells. (D) Representative H&E staining for tumor cytostructures (scale bars, 2.5 mm). PBS: U87/luciferase cells pretreated with PBS, TR EXO: U87/luciferase cells pretreated with U87 TR cells-derived exosomes, TR NC EXO: U87/luciferase cells pretreated with the exosomes derived from U87TR-NC cells, TR MIF-sh EXO: U87/luciferase cells pretreated with the exosomes derived from U87TR-MIF-sh cells. (E–G) U87TR/luciferase cells were orthotopically implanted into the brain of BALB/c mice. DMSO, ISO, LY294002, or ISO+LY294002 (n = 5 per group) were injected (i.p.) into the mice twice per week for 28 days. (E) Representative pseudocolor bioluminescence images of orthotopic tumors. (F) Kaplan-Meier survival curve of mice with different treatment. (G) Representative H&E staining for tumor cytostructures (scale bars, 2.5 mm). ∗∗p＜0.01.